Hematológia

Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F

Zdroj‎: Blood Adv. 2022;6(3):785-92.

Označenie‎: PubMed 34781363

Identifikátor digitálneho objektu‎: 10.1182/bloodadvances.2021005627

https://pubmed.ncbi.nlm.nih.gov/34781363/ (otvorí nové okno)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (otvorí nové okno)

Leahy MF, Trentino KM, May C, Swain SG, Chuah H, Farmer SL.

Zdroj‎: Transfusion 2017;57(9):2189-96.

Označenie‎: PubMed 28671296

Identifikátor digitálneho objektu‎: 10.1111/trf.14191

https://www.ncbi.nlm.nih.gov/pubmed/28671296 (otvorí nové okno)

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (otvorí nové okno)

Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K, Billet A, Sloan S, Lehmann LE.

Zdroj‎: Biol Blood Marrow Transplant 2012;18(5):813-7.

Označenie‎: PubMed 22080050

Identifikátor digitálneho objektu‎: 10.1016/j.bbmt.2011.10.043

https://www.ncbi.nlm.nih.gov/pubmed/22080050 (otvorí nové okno)

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (otvorí nové okno)

McQuilten ZK, Higgins AM, Burns K, Chunilal S, Dunstan T, Haysom HE, Kaplan Z, Rushford K, Saxby K, Tahiri R, Waters N, Wood EM.

Zdroj‎: Transfusion 2019;59(11):3386-95.

Označenie‎: PubMed 31664712

Identifikátor digitálneho objektu‎: 10.1111/trf.15558

https://www.ncbi.nlm.nih.gov/pubmed/31664712 (otvorí nové okno)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvorí nové okno)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Zdroj‎: Transfusion 2015;55(12):2807-15.

Označenie‎: PubMed 26264557

Identifikátor digitálneho objektu‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (otvorí nové okno)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvorí nové okno)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Zdroj‎: Cancer 2013;119(1):107-14.

Označenie‎: PubMed 22744794

Identifikátor digitálneho objektu‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (otvorí nové okno)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (otvorí nové okno)

Nikolaidi E, Hatzikou M, Geitona M.

Zdroj‎: Cost Eff Resour Alloc 2013;11(1):16.

Označenie‎: PubMed 23870502

Identifikátor digitálneho objektu‎: 10.1186/1478-7547-11-16

https://www.ncbi.nlm.nih.gov/pubmed/23870502 (otvorí nové okno)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvorí nové okno)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Zdroj‎: Support Care Cancer 2012;20(1):159-65.

Označenie‎: PubMed 21359879

Identifikátor digitálneho objektu‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (otvorí nové okno)

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (otvorí nové okno)

Pettigrew M, Garces K, Deuson R, Kassis J, Laroche V

Zdroj‎: J Med Econ 2013;16(2):318-26.

Označenie‎: PubMed 23216012

Identifikátor digitálneho objektu‎: 10.3111/13696998.2012.756400

https://www.ncbi.nlm.nih.gov/pubmed/23216012 (otvorí nové okno)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (otvorí nové okno)

Ravangard R, Mirzaei Z, Keshavarz K, Haghpanah S, Karimi M.

Zdroj‎: Hematology 2018;23(7):417-22.

Označenie‎: PubMed 29157136

Identifikátor digitálneho objektu‎: 10.1080/10245332.2017.1404262

https://www.ncbi.nlm.nih.gov/pubmed/29157136 (otvorí nové okno)

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (otvorí nové okno)

Reitan JF, Kudrik FJ, Fox K, van Breda A, Shreay S, Corey-Lisle PK.

Zdroj‎: J Med Econ 2013;16(5):633-8.

Označenie‎: PubMed 23425291

Identifikátor digitálneho objektu‎: 10.3111/13696998.2013.778269

https://www.ncbi.nlm.nih.gov/pubmed/23425291 (otvorí nové okno)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (otvorí nové okno)

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

Zdroj‎: Transfusion 2010;50(2):487-92.

Označenie‎: PubMed 19804569

Identifikátor digitálneho objektu‎: 10.1111/j.1537-2995.2009.02413.x

https://www.ncbi.nlm.nih.gov/pubmed/19804569 (otvorí nové okno)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (otvorí nové okno)

Stallworth JR, Jerrell JM, Tripathi A.

Zdroj‎: Am J Hematol 2010;85(10):795-7.

Označenie‎: PubMed 20645429

Identifikátor digitálneho objektu‎: 10.1002/ajh.21772

https://www.ncbi.nlm.nih.gov/pubmed/20645429 (otvorí nové okno)

Increased hospital costs associated with red blood cell transfusion. (otvorí nové okno)

Trentino KM, Farmer SL, Swain SG, Burrows SA, Hofmann A, Ienco R, Pavey W, Daly FF, Van Niekerk A, Webb SA, Towler S, Leahy MF.

Zdroj‎: Transfusion 2015;55(5):1082-9.

Označenie‎: PubMed 25488623

Identifikátor digitálneho objektu‎: 10.1111/trf.12958

https://www.ncbi.nlm.nih.gov/pubmed/25488623 (otvorí nové okno)

EKONOMICKÉ VÝHODY ALTERNATÍVNYCH POSTUPOV K TRANSFÚZII KRVI

Hematológia

slovenčina

Hematológia

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (otvorí nové okno)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (otvorí nové okno)

Restrictive blood transfusion practices are associated with improved patient outcomes. (otvorí nové okno)

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (otvorí nové okno)

Recombinant activated factor VII use in critically ill infants with active hemorrhage. (otvorí nové okno)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (otvorí nové okno)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (otvorí nové okno)

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (otvorí nové okno)

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (otvorí nové okno)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvorí nové okno)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvorí nové okno)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (otvorí nové okno)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvorí nové okno)

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (otvorí nové okno)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (otvorí nové okno)

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (otvorí nové okno)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (otvorí nové okno)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (otvorí nové okno)

Increased hospital costs associated with red blood cell transfusion. (otvorí nové okno)

Výbor pre styk s nemocnicami (VSN)

Informačné balíčky pre lekárov

Videá

Hematológia

Vyberte si jazyk

Poslať odkaz